Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug - STAT

Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug - STAT
Business

Listen to this article

0%

The Food and Drug Administration said Monday that Capricor Therapeutics stem cell treatment for Duchenne muscular dystrophy did not meet the objectives of a Phase 3 trial contrary to the companys cla… [+824 chars]

Leave A Comment

Comments are moderated and may take time to appear.

Comments

No comments yet. Be the first to comment!

Stay Connected